ReviewJournal of thoracic disease2020
Pulmonary enteric adenocarcinoma: a literature review.
Review in Journal of thoracic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Recent advances in diagnostic and therapeutic approaches for pulmonary enteric adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- The clinicopathologic characteristics and tumor immune microenvironment of pulmonary enteric adenocarcinoma.Annals of medicine · 2025Article
- A challenging case of enteric-type lung adenocarcinoma metastatic to the thyroid harboring RET-fusion diagnosed on fine-needle aspiration.Virchows Archiv : an international journal of pathology · 2025Article
- [A Case of Refractory Pulmonary Enteric Adenocarcinoma with EGFR Sensitive Mutation].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Article
- Double the trouble: pulmonary enteric adenocarcinoma with synchronous contralateral pulmonary adenocarcinoma.Oxford medical case reports · 2025Article
- Case Report: Controversies in managing pulmonary enteric adenocarcinoma: reflections from an early-stage case.Frontiers in oncology · 2025Article
- Case Report: Pulmonary enteric adenocarcinoma harboring KRAS/TP53/APC mutations with contralateral lung metastasis: diagnostic challenges and molecular insights.Frontiers in oncology · 2025Article
- Pulmonary enteric adenocarcinoma with progression disease after second - line therapy: a case report.Frontiers in oncology · 2025Article
- Case report: Pathological complete response of pregnancy associated pulmonary enteric adenocarcinoma to chemoradiotherapy.Frontiers in oncology · 2024Article
- Case report:Frontiers in oncology · 2024Article
- Lung enteric-type adenocarcinoma with gastric metastasis: a rare case report and literature review.Frontiers in immunology · 2024Review
- Lymph node and bone metastasis of pulmonary intestinal adenocarcinoma: A case report.Oncology letters · 2023Article
- Deciphering Lung Adenocarcinoma Heterogeneity: An Overview of Pathological and Clinical Features of Rare Subtypes.Life (Basel, Switzerland) · 2023Review
- A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.The Journal of pathology · 2023Article
- Clinical features and prognosis of pulmonary enteric adenocarcinoma: A retrospective study in China and the SEER database.Frontiers in oncology · 2023Article
- Case report: Target and immunotherapy of a lung adenocarcinoma with enteric differentiation,Frontiers in immunology · 2023Article
- A pulmonary enteric adenocarcinoma patient harboring a rare EGFR exon 19 P753S mutation: Case report and review.Frontiers in oncology · 2022Article
- Hyperprogressive Disease After Immunotherapy: A Case Report of Pulmonary Enteric Adenocarcinoma.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary enteric adenocarcinoma (PEAC) is an extremely rare type of non-small cell lung cancer (NSCLC) with a histologic pattern that mimics metastatic colorectal cancer (MCC). The main clinical symptoms in PEAC patients are dyspnoea, coughing, hemoptysis, and chest and back pain. The first article about PEAC appeared in 1991 in the form of a case report. As a variant of invasive lung carcinoma, only a small number of case reports and clinical research studies have been carried out, and the only one guidance on diagnosis and treatment is the WHO Tumor Classification book. It is important for doctors to distinguish PEAC from MCC to extend survival time and improve the quality of life. We reviewed the existing literature regarding the diagnosis, treatment, and prognosis of PEAC to provide some valuable clinical references.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.